

Ref: FOI/GS/ID 4744

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

7 June 2018

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Intra-vitreous injections and implants.

You asked:

*Within your trust how many intra-vitreous injections/implants have been used in the latest 4 months, if possible between January to April 2018
If your trust is able to identify injections/implants by eye conditions please split by the drug used [ranibizumab, bevacizumab, aflibercept, Fluocinolone and Dexamethasone].*

Trust response:

Please see the following table.

Please note figures are for December 2017 to March 2018

| | <i>Lucentis (ranibizumab) Injections</i> | <i>Avastin (bevacizumab) Injections</i> | <i>Eylea (aflibercept) Injections</i> | <i>Illuvien (Fluocinolone) Impants</i> | <i>Ozudex (Dexamethasone) Implants</i> |
|--|--|---|---|--|--|
| Total | 544 | 10 | 861 | 0 | 50 |
| <i>Wet Age Related Macular Degeneration (wAMD)</i> | 295 | 1 | 673 | 0 | 0 |
| <i>Diabetic Macular Oedema (DMO)</i> | 116 | 8 | 130 | 0 | 19 |
| <i>Retinal Vein Occlusion - Central or Branch (CRVO or BRVO)</i> | 132 | 1 | 58 | 0 | 25 |
| <i>Other eg mCNV</i> | 1 | 0 | 0 | 0 | 6 |

